Shares of AstraZeneca (NASDAQ: AZN) have jumped more than 10% this week. On Monday, the British drugmaker reported positive results from a clinical study of Enhertu in treating HER2-positive early ...
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
Thermo Fisher Scientific announced an R&D partnership with AstraZeneca BioVentureHub. Crinetics received FDA approval of Palsonify (paltusotine) to treat acromegaly in adults. The agency approved ...
By Charlie Conchie LONDON (Reuters) -AstraZeneca’s move to upgrade its listing in the U.S. risks pulling liquidity away from ...
AstraZeneca said on Friday it will sell its diabetes and asthma drugs direct to cash-paying U.S. patients at a discount of up ...
The PPD™ clinical research business of Thermo Fisher Scientific, the world leader in serving science, today announced a new ...
AstraZeneca is the latest big pharma group to open up a Direct-To-Consumer (DTC) sales channel in the US, offering three of ...
AstraZeneca plans to upgrade its U.S. listing, retaining UK roots but expanding into the New York Stock Exchange. This move ...
AstraZeneca plans to list its shares in New York while keeping its London listing, a move that could allow easier access to ...
AstraZeneca Plc (NASDAQ: AZN) launched AstraZeneca Direct, an online platform designed to create a simple, convenient way for ...
AstraZeneca is a leading global pharmaceutical company with strong growth in oncology, diversified revenues, and a robust ...
Cambridge headquartered life science giant AstraZeneca saw its UK share price rocket 86p and market cap rise to £1781.5 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback